title: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
abstract: OBJECTIVE
  This phase III randomized open-label clinical trial was designed to evaluate the efficacy and safety of the steroidal aromatase inactivator exemestane versus the antiestrogen tamoxifen as first-line treatment for metastatic breast cancer (MBC) in postmenopausal women.
  
  
  METHODS
  The study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone-sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or tamoxifen were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive exemestane 25 mg or tamoxifen 20 mg orally once daily until disease progression or unacceptable toxicity occurred.
  
  
  RESULTS
  A total of 371 patients enrolled at 79 sites (182 exemestane, 189 tamoxifen) were included in the analysis. Both treatments were generally well tolerated without major toxicity. Overall response rate was greater for exemestane than for tamoxifen treatment (46% v 31%; odds ratio = 1.85; 95% CI, 1.21 to 2.82; P = .005). Median progression-free survival (PFS) was longer with exemestane (9.9 months; 95% CI, 8.7 to 11.8 months) than with tamoxifen (5.8 months; 95% CI, 5.3 to 8.1 months). However, these early differences (Wilcoxon P = .028) did not translate to a longer-term benefit in PFS, the primary study end point (log-rank P = .121). There was also no difference in survival between both study arms.
  
  
  CONCLUSIONS
  Exemestane is an effective and well-tolerated first-line hormonal treatment for postmenopausal women with MBC and offers significant early improvement in time to tumor progression when compared with tamoxifen.
authors.affiliation: University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium. robert.paridaens@uz.kuleuven.ac.be
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Paridaens
authors.forename: Luc Y
authors.initials: LY
authors.lastname: Dirix
authors.forename: Louk V
authors.initials: LV
authors.lastname: Beex
authors.forename: Marianne
authors.initials: M
authors.lastname: Nooij
authors.forename: David A
authors.initials: DA
authors.lastname: Cameron
authors.forename: Tanja
authors.initials: T
authors.lastname: Cufer
authors.forename: Martine J
authors.initials: MJ
authors.lastname: Piccart
authors.forename: Jan
authors.initials: J
authors.lastname: Bogaerts
authors.forename: Patrick
authors.initials: P
authors.lastname: Therasse
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D017698:Postmenopause; D012983:Soft Tissue Neoplasms / Q000556:secondary; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D013629:Tamoxifen; C056516:exemestane
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Ann Oncol. 2003 Sep;14(9):1391-8
references.pmid: 12954578
references.citation: Lancet. 2002 Jun 22;359(9324):2131-9
references.pmid: 12090977
references.citation: Cancer. 2008 Jan 15;112(2):260-7
references.pmid: 18041059
references.citation: J Clin Oncol. 1995 Feb;13(2):513-29
references.pmid: 7844613
references.citation: Ann Oncol. 1999 Apr;10(4):377-84
references.pmid: 10370778
references.citation: J Clin Oncol. 2001 May 15;19(10):2596-606
references.pmid: 11352951
references.citation: Anticancer Drugs. 1998 Sep;9(8):675-83
references.pmid: 9823425
references.citation: Cancer. 2003 Nov 1;98(9):1802-10
references.pmid: 14584060
references.citation: J Clin Oncol. 1999 Nov;17(11):3418-25
references.pmid: 10550136
references.citation: J Clin Oncol. 2000 Jun;18(11):2234-44
references.pmid: 10829043
references.citation: Lancet. 2007 Feb 17;369(9561):559-70
references.pmid: 17307102
references.citation: Eur J Cancer. 1997 Oct;33(11):1767-73
references.pmid: 9470830
references.citation: J Clin Oncol. 2000 Apr;18(7):1399-411
references.pmid: 10735887
references.citation: N Engl J Med. 2005 Dec 29;353(26):2747-57
references.pmid: 16382061
references.citation: J Clin Oncol. 2000 Nov 15;18(22):3748-57
references.pmid: 11078487
references.citation: J Clin Oncol. 2003 Jun 1;21(11):2101-9
references.pmid: 12775735
references.citation: Biometrics. 1975 Mar;31(1):103-15
references.pmid: 1100130
references.citation: Expert Opin Pharmacother. 2004 Feb;5(2):307-16
references.pmid: 14996627
references.citation: Ann Oncol. 2004 Feb;15(2):211-7
references.pmid: 14760111
references.citation: J Clin Oncol. 2000 Nov 15;18(22):3758-67
references.pmid: 11078488
references.citation: Ann Oncol. 2005 Jan;16(1):70-4
references.pmid: 15598941